Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efbemalenograstim alfa
- Development stage
- Approved
- Lead developer
- Evive Biotech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) fused to the Fc portion of human IgG2. It is used to decrease the incidence and duration of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. The drug acts by binding to G-CSF receptors in bone marrow, stimulating progenitor cell differentiation, proliferation, and mobilization of granulocytes (neutrophils), thereby reducing the severity and duration of neutropenia. Its prolonged half-life allows for once-per-cycle administration. Efbemalenograstim alfa was developed as an alternative to other G-CSF agents such as pegfilgrastim and filgrastim[2][5][6][8].
- Brand names
- Ryzneutaefbemalenograstim alfa-vuxw
- Other names
- bemalenograstim alfa
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on efbemalenograstim alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efbemalenograstim alfa.